NCT06686329Recruiting
Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose
Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose: The MISSED DOSE Study
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
People living with type 1 diabetes (PwT1D) are recommended to administer insulin 10-15 minutes before meal consumption (pre-bolus), to account for the delay in the glucose lowering action associated with subcutaneously administered insulin. Due to the demands of day-to-day life, pre-bolusing is not always possible or may be forgotten. With continuous glucose monitors (CGMs), PwT1D may be alerted to this missed insulin dose by a CGM alert, including rapidly rising glucose (change \>2.5mmol/L/15min) or hyperglycemia (\>10.0 mmol/L), and deliver a mistimed (post-prandial) dose in response to CGM alert. This study was designed to determine the effect of combining a post-prandial/mistimed insulin dose with 15 minutes of brisk walking. It is expected that walking will help to minimize or prevent hyperglycemia after a mistimed bolus insulin dose, as well as blunt the rise in glucose following a mistimed insulin dose.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 6 Nov 2024
- Start date
- 17 Mar 2025
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Jane Yardley
- Diseases
- Type 1 diabetes
- NCT number
- NCT06686329
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 17 Mar 2025 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Having a condition that could render exercise harmful
- Having significant renal disease (e.g., eGRF \< 30 ml/min)
Lab values
- Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been stable for more than three months
Other
- Changes in insulin management strategy within the past 2 months
- Diagnosis of gastroparesis
- Intolerance to gluten and lactose
- Inability to provide informed consent due to cognitive deficit
- For women, being pregnant or breastfeeding
Who the study is looking for
- Adults aged 18-24 years
- Type 1 diabetes diagnostic for at least two years
- Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of \< 9.9%
- Use a Dexcom G7 CGM in routine care
Age in the registry: 18 years to 24 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Recherches Cliniques de Montreal Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.